[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-03 Novel mechanisms,,"},{"Key":"Keywords","Value":"Chemoresistance,Import mechanisms,Platinum drugs,Bladder cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. R. Feldman<\/b><sup>1<\/sup>, S. Mohapatra<sup>2<\/sup>, R. Jones<sup>1<\/sup>, C. Tilton<sup>1<\/sup>, T. Zuiverloon<sup>3<\/sup>, J. Costello<sup>1<\/sup>, D. Theodorescu<sup>2<\/sup>; <br\/><sup>1<\/sup>University of Colorado Anschutz Medical Campus, Aurora, CO, <sup>2<\/sup>Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, <sup>3<\/sup>Erasmus University Medical Center, Rotterdam, Netherlands","CSlideId":"","ControlKey":"8194d346-2987-471d-b081-b4ad79d450eb","ControlNumber":"10740","DisclosureBlock":"&nbsp;<b>L. R. Feldman, <\/b> None..<br><b>S. Mohapatra, <\/b> None..<br><b>R. Jones, <\/b> None..<br><b>C. Tilton, <\/b> None..<br><b>T. Zuiverloon, <\/b> None..<br><b>J. Costello, <\/b> None..<br><b>D. Theodorescu, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10504","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB256","PresenterBiography":null,"PresenterDisplayName":"LILY ELIZABETH Feldman","PresenterKey":"fd284093-5b98-43bc-85eb-036a51cda906","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB256. New mechanistic insights into cisplatin resistance in muscle-invasive bladder cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"New mechanistic insights into cisplatin resistance in muscle-invasive bladder cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-03 Novel mechanisms,,"},{"Key":"Keywords","Value":"Renal cell carcinoma,Signaling pathways,Cancer immunotherapy,Drug resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J.-S. Chung<\/b>, L. Guo, V. Popat, P. D. Cruz, Jr., L. Xu, H. Hammers, K. Ariizumi; <br\/>UT Southwestern Medical Center, Dallas, TX","CSlideId":"","ControlKey":"823e3f08-cf80-4452-8a07-4b0442469f86","ControlNumber":"9707","DisclosureBlock":"&nbsp;<b>J. Chung, <\/b> None..<br><b>L. Guo, <\/b> None..<br><b>V. Popat, <\/b> None..<br><b>P. D. Cruz, <\/b> None..<br><b>L. Xu, <\/b> None..<br><b>H. Hammers, <\/b> None..<br><b>K. Ariizumi, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10505","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB257","PresenterBiography":"","PresenterDisplayName":"Jin-Sung Chung, PhD","PresenterKey":"f271bd2c-324d-4d4c-a117-989b5194ba43","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB257. Possible involvement of PDL1 intrinsic signaling to acquired resistance to immunotherapy for renal cell carcinoma (RCC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Possible involvement of PDL1 intrinsic signaling to acquired resistance to immunotherapy for renal cell carcinoma (RCC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-03 Novel mechanisms,,"},{"Key":"Keywords","Value":"ABC transporters,Post-transcriptional regulation,Drug resistance,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Ji<\/b><sup>1<\/sup>, X. Peng<sup>2<\/sup>, Y.-n. Liu<sup>2<\/sup>, Y. Yang<sup>3<\/sup>, Z.-S. Chen<sup>3<\/sup>, D. Kong<sup>2<\/sup>, Y. Li<sup>1<\/sup>; <br\/><sup>1<\/sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, <sup>2<\/sup>Tianjin Medical University, Tianjin, China, <sup>3<\/sup>St. John's University, New York, NY","CSlideId":"","ControlKey":"8be32ce0-e1cc-455a-9ad1-2565d25d0004","ControlNumber":"10628","DisclosureBlock":"&nbsp;<b>N. Ji, <\/b> None..<br><b>X. Peng, <\/b> None..<br><b>Y. Liu, <\/b> None..<br><b>Y. Yang, <\/b> None..<br><b>Z. Chen, <\/b> None..<br><b>D. Kong, <\/b> None..<br><b>Y. Li, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10506","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB258","PresenterBiography":null,"PresenterDisplayName":"Ning Ji, Dr PH","PresenterKey":"543e6dde-fb4a-43ac-aac8-59d0e1fb85a1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB258. ZDHHC20 is a potential target for overcoming ABCB1-mediated multidrug resisance (MDR) in cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"ZDHHC20 is a potential target for overcoming ABCB1-mediated multidrug resisance (MDR) in cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-04 Regulation of gene expression in drug resistance,,"},{"Key":"Keywords","Value":"Prostate cancer,KDM5D,Chk1,ATR,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>W. Zheng<\/b>, Y. Chen, Q. J. Wang; <br\/>University of Pittsburgh, Pittsburgh, PA","CSlideId":"","ControlKey":"74734c59-35f2-4a16-9999-e09578ca07d2","ControlNumber":"10443","DisclosureBlock":"&nbsp;<b>W. Zheng, <\/b> None..<br><b>Y. Chen, <\/b> None..<br><b>Q. J. Wang, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10507","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB259","PresenterBiography":null,"PresenterDisplayName":"Wenxiao Zheng, MS,MD","PresenterKey":"a1613427-bb77-4924-b8a4-83f7b9086e1f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB259. Cell context-dependent role of KDM5D in ATR and CHK1 inhibitor sensitivity in prostate cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Cell context-dependent role of KDM5D in ATR and CHK1 inhibitor sensitivity in prostate cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-04 Regulation of gene expression in drug resistance,,"},{"Key":"Keywords","Value":"Ovarian cancer,PARP inhibitors,ABC transporters,Drug resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Fang<\/b><sup>1<\/sup>, X. Fang<sup>2<\/sup>; <br\/><sup>1<\/sup>Shuo Fang (Individual), Shenzhen, China, <sup>2<\/sup>Sun Yat-sen University, Guangzhou, China","CSlideId":"","ControlKey":"f0ffc5ee-7afa-44d1-a2d4-ca784b852b19","ControlNumber":"10534","DisclosureBlock":"&nbsp;<b>S. Fang, <\/b> None..<br><b>X. Fang, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10508","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB260","PresenterBiography":null,"PresenterDisplayName":"Shuo Fang, M Phil","PresenterKey":"8ad193df-aeb9-4e5b-abea-2c7941c33301","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB260. Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly polymerase inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly polymerase inhibitor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET03-06 Other,,"},{"Key":"Keywords","Value":"Drug resistance,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L.-H. Yih<\/b>, H.-H. Kuo, C.-T. Fang; <br\/>Academia Sinica - Institute of Cellular & Organismic Biology, Taipei, Taiwan","CSlideId":"","ControlKey":"9b38dd03-29ab-4807-9ee3-c825c6a3a17e","ControlNumber":"9596","DisclosureBlock":"&nbsp;<b>L. Yih, <\/b> None..<br><b>H. Kuo, <\/b> None..<br><b>C. Fang, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10509","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB261","PresenterBiography":null,"PresenterDisplayName":"Ling-Huei Yih, PhD","PresenterKey":"f9d6b02e-7873-44ec-bea0-0d940ef9b15e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB261. Establishment and characterization of a paclitaxel&#8209;resistant human triple-negative breast cancer cell line","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Establishment and characterization of a paclitaxel&#8209;resistant human triple-negative breast cancer cell line","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET04-02 Gene therapy and radiation studies,,"},{"Key":"Keywords","Value":"Oncolytic virus,Glioblastoma,Insulin-like growth factor 2 (IGF-2),Tumor microenvironment,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"M. Noh<sup>1<\/sup>, A. Miller<sup>1<\/sup>, G. Nguyen<sup>1<\/sup>, H. Nakashima<sup>2<\/sup>, E. Chiocca<sup>2<\/sup>, B. Kaur<sup>3<\/sup>, Z. Zhao<sup>1<\/sup>, <b>T. Lee<\/b><sup>1<\/sup>, J. Yoo<sup>1<\/sup>; <br\/><sup>1<\/sup>UT Health Houston, Houston, TX, <sup>2<\/sup>Harvard Medical School, Boston, MA, <sup>3<\/sup>Augusta University, Augusta, GA","CSlideId":"","ControlKey":"e0e4a5b2-7465-47ba-b8a0-eaaf1bee4ac2","ControlNumber":"10772","DisclosureBlock":"&nbsp;<b>M. Noh, <\/b> None..<br><b>A. Miller, <\/b> None..<br><b>G. Nguyen, <\/b> None..<br><b>H. Nakashima, <\/b> None..<br><b>E. Chiocca, <\/b> None..<br><b>B. Kaur, <\/b> None..<br><b>Z. Zhao, <\/b> None..<br><b>T. Lee, <\/b> None..<br><b>J. Yoo, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10510","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB262","PresenterBiography":null,"PresenterDisplayName":"Tae Jin Lee, PhD","PresenterKey":"06312f3e-6c06-48de-a3fa-82ea6de3d7f6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB262. Reprogramming the tumor microenvironment by targeting IGF2-IGF1R signaling, enhancing viro-immunotherapy","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Reprogramming the tumor microenvironment by targeting IGF2-IGF1R signaling, enhancing viro-immunotherapy","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET04-03 Immune modulators,,"},{"Key":"Keywords","Value":"Immune checkpoint blockade,Oncolytic virus,B cells,T cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. R. Diers<\/b><sup>1<\/sup>, Q. Guo<sup>1<\/sup>, J. D. Christie<sup>1<\/sup>, D. Krisky<sup>1<\/sup>, F. M. Gaspal<sup>2<\/sup>, E. Richardson<sup>2<\/sup>, C. G. Smith<sup>3<\/sup>, D. R. Withers<sup>2<\/sup>, A. P. Croft<sup>3<\/sup>, P. P. Tak<sup>1<\/sup>, F. Barone<sup>1<\/sup>; <br\/><sup>1<\/sup>Candel Therapeutics, Needham, MA, <sup>2<\/sup>Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, <sup>3<\/sup>Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom","CSlideId":"","ControlKey":"a3e92640-d7d2-4204-88fc-90e8d1a230ea","ControlNumber":"10384","DisclosureBlock":"<b>&nbsp;A. R. Diers, <\/b> <br><b>Candel Therapeutics<\/b> Employment, Stock Option. <br><b>Q. Guo, <\/b> <br><b>Candel Therapeutics<\/b> Employment, Stock Option. <br><b>J. D. Christie, <\/b> <br><b>Candel Therapeutics<\/b> Employment, Stock Option. <br><b>D. Krisky, <\/b> <br><b>Candel Therapeutics<\/b> Other Intellectual Property. <br><b>F. M. Gaspal, <\/b> <br><b>Candel Therapeutics<\/b> Grant\/Contract. <br><b>E. Richardson, <\/b> <br><b>Candel Therapeutics<\/b> Grant\/Contract. <br><b>C. G. Smith, <\/b> <br><b>Candel Therapeutics<\/b> Grant\/Contract. <br><b>D. R. Withers, <\/b> <br><b>Candel Therapeutics<\/b> Grant\/Contract. <br><b>A. P. Croft, <\/b> <br><b>Candel Therapeutics<\/b> Grant\/Contract. <br><b>P. P. Tak, <\/b> <br><b>Candel Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>F. Barone, <\/b> <br><b>Candel Therapeutics<\/b> Employment, Stock, Stock Option.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10511","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB263","PresenterBiography":null,"PresenterDisplayName":"Anne Diers, PhD","PresenterKey":"98b11cd3-e220-4f47-8d28-d49b67a038c5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB263. A first-in-class multimodal immunotherapy for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-class multimodal immunotherapy for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET04-04 Vector systems and targeting strategies,,"},{"Key":"Keywords","Value":"Peritoneal metastasis,Adeno associated virus,MicroRNA,Mesothelium,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Kaneko<\/b>, H. Ohzawa, Y. Kimura, R. Takahashi, M. Matsumiya, K. Tamura, Y. Futoh, H. Miyato, R. Watano, H. Mizukami, N. Sata, J. Kitayama; <br\/>Jichi Medical University, Shimotsuke, Japan","CSlideId":"","ControlKey":"3db54f42-58aa-42de-b95e-3320ff702348","ControlNumber":"9829","DisclosureBlock":"&nbsp;<b>Y. Kaneko, <\/b> None..<br><b>H. Ohzawa, <\/b> None..<br><b>Y. Kimura, <\/b> None..<br><b>R. Takahashi, <\/b> None..<br><b>M. Matsumiya, <\/b> None..<br><b>K. Tamura, <\/b> None..<br><b>Y. Futoh, <\/b> None..<br><b>H. Miyato, <\/b> None..<br><b>R. Watano, <\/b> None..<br><b>H. Mizukami, <\/b> None..<br><b>N. Sata, <\/b> None..<br><b>J. Kitayama, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10512","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB264","PresenterBiography":null,"PresenterDisplayName":"Yuki Kaneko, MD","PresenterKey":"bcd471a5-fc3d-4e7a-92ba-9d6148e58b27","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB264. Intracavitary gene therapy using miRNA-29b-encoding adeno-associated virus for peritoneal dissemination","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Intracavitary gene therapy using miRNA-29b-encoding adeno-associated virus for peritoneal dissemination","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET05-01 Cell cycle mechanisms of anticancer drug action,,"},{"Key":"Keywords","Value":"p27KIP1,CDK4\/6 inhibitors,CDK2,CDK4\/6i-resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"G. Chen, N. Dudas, K. Coleman, C. Guido, N. Zisman, K. Allamneni, <b>S. W. Blain<\/b>; <br\/>Concarlo Therapeutics, Brooklyn, NY","CSlideId":"","ControlKey":"a931638d-6d73-42c2-be4d-1993bc6f35d1","ControlNumber":"10459","DisclosureBlock":"&nbsp;<b>G. Chen, <\/b> None..<br><b>N. Dudas, <\/b> None..<br><b>K. Coleman, <\/b> None..<br><b>C. Guido, <\/b> None..<br><b>N. Zisman, <\/b> None..<br><b>K. Allamneni, <\/b> None..<br><b>S. W. Blain, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10513","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB265","PresenterBiography":null,"PresenterDisplayName":"Stacy Blain, PhD","PresenterKey":"543c39bb-34b6-4cc6-b6fd-d4a8226f4c10","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB265. IpY.20: Innovative strategies for post-CDK estrogen receptor (ER)+ metastatic breast cancer (mBC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"IpY.20: Innovative strategies for post-CDK estrogen receptor (ER)+ metastatic breast cancer (mBC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-01 Cell death pathways and treatment,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,Cell death,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. Luo<\/b><sup>1<\/sup>, A. Li<sup>1<\/sup>, W. Du<sup>1<\/sup>, M. Chen<sup>1<\/sup>, J. Li<sup>2<\/sup>, Y. Zhou<sup>3<\/sup>, L. Zhang<sup>1<\/sup>, S. Hong<sup>1<\/sup>; <br\/><sup>1<\/sup>Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Guangzhou, China, <sup>2<\/sup>Department of Experimental research, Sun Yat-sen University Cancer Center, Guangzhou, China, Guangzhou, China, <sup>3<\/sup>Department of VIP region, Sun Yat-sen University Cancer Center, Guangzhou, China, Guangzhou, China","CSlideId":"","ControlKey":"018387d9-c259-4c61-ba98-a67af0485258","ControlNumber":"10259","DisclosureBlock":"&nbsp;<b>L. Luo, <\/b> None..<br><b>A. Li, <\/b> None..<br><b>W. Du, <\/b> None..<br><b>M. Chen, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>Y. Zhou, <\/b> None..<br><b>L. Zhang, <\/b> None..<br><b>S. Hong, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10514","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB266","PresenterBiography":null,"PresenterDisplayName":"?? ?, MD","PresenterKey":"eb67ee9b-9f50-4196-8ce3-0074478978a7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB266. AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-01 Cell death pathways and treatment,,"},{"Key":"Keywords","Value":"Reactive oxygen species,Ferroptosis,novel anti-cancer mechanism,Colorectal cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. R. Gaikwad, <b>M. A. Eltokhy<\/b>, M. Moore, K. Kailath, S. K. Srivastava; <br\/>Texas Tech University Health Sciences Center, Abilene, TX","CSlideId":"","ControlKey":"45a0d553-bce4-4f26-99db-edac9339a502","ControlNumber":"10736","DisclosureBlock":"&nbsp;<b>S. R. Gaikwad, <\/b> None..<br><b>M. A. Eltokhy, <\/b> None..<br><b>M. Moore, <\/b> None..<br><b>K. Kailath, <\/b> None..<br><b>S. K. Srivastava, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10515","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB267","PresenterBiography":null,"PresenterDisplayName":"Mohamed Eltokhy, B Pharm,MS","PresenterKey":"f99dbb8b-24bf-4e7f-af54-cf97efb5ad79","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB267. Disrupting cytoplasmic proton motive force induces ferroptotic cell death in colorectal cancer: A novel anti-cancer mechanism","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Disrupting cytoplasmic proton motive force induces ferroptotic cell death in colorectal cancer: A novel anti-cancer mechanism","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-02 DNA damage and repair,,"},{"Key":"Keywords","Value":"Synthetic lethality,PARP1 inhibitor,Selective,Brain-penetrating,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Gao, Y. Lu, B. Chen, B. Jiang, F. Wang, G. Zhang, X. Ma, D. Zhou, C. Shi, Y. Wang, Z. Liu, J. Sun, H. Zhou, <b>M. Xu<\/b>, J. Li, B. Liu; <br\/>Xuanzhu Biopharmaceutical Co. Ltd., Beijing, China","CSlideId":"","ControlKey":"b37c720b-cd10-4e3f-8a4d-d661926da658","ControlNumber":"10481","DisclosureBlock":"&nbsp;<b>Y. Gao, <\/b> None..<br><b>Y. Lu, <\/b> None..<br><b>B. Chen, <\/b> None..<br><b>B. Jiang, <\/b> None..<br><b>F. Wang, <\/b> None..<br><b>G. Zhang, <\/b> None..<br><b>X. Ma, <\/b> None..<br><b>D. Zhou, <\/b> None..<br><b>C. Shi, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>Z. Liu, <\/b> None..<br><b>J. Sun, <\/b> None..<br><b>H. Zhou, <\/b> None..<br><b>M. Xu, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>B. Liu, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10516","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB268","PresenterBiography":null,"PresenterDisplayName":"Mei Xu, PhD","PresenterKey":"d8cc4d93-705f-4d3c-abf9-ac69228df8b6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB268. Discovery of a potent, selective and brain penetrating PARP1 inhibitor, XZP-7797<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discovery of a potent, selective and brain penetrating PARP1 inhibitor, XZP-7797<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-02 DNA damage and repair,,"},{"Key":"Keywords","Value":"Synthetic lethality,USP1 inhibitor,Potent,Selective,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Z. Kan, S. Bai, K. Ma, B. Chen, B. Jiang, F. Wang, X. Ma, D. Zhou, C. Shi, Y. Nie, Y. Wang, R. Liu, J. Sun, H. Zhou, <b>M. Xu<\/b>, J. Li, B. Liu; <br\/>Xuanzhu Biopharmaceutical Co. Ltd., Beijing, China","CSlideId":"","ControlKey":"b2c82d0d-68f0-463c-8489-7905a1e9e28f","ControlNumber":"10292","DisclosureBlock":"&nbsp;<b>Z. Kan, <\/b> None..<br><b>S. Bai, <\/b> None..<br><b>K. Ma, <\/b> None..<br><b>B. Chen, <\/b> None..<br><b>B. Jiang, <\/b> None..<br><b>F. Wang, <\/b> None..<br><b>X. Ma, <\/b> None..<br><b>D. Zhou, <\/b> None..<br><b>C. Shi, <\/b> None..<br><b>Y. Nie, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>R. Liu, <\/b> None..<br><b>J. Sun, <\/b> None..<br><b>H. Zhou, <\/b> None..<br><b>M. Xu, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>B. Liu, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10517","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB269","PresenterBiography":null,"PresenterDisplayName":"Mei Xu, PhD","PresenterKey":"d8cc4d93-705f-4d3c-abf9-ac69228df8b6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB269. XZP-6924: A potent and highly selective USP1 inhibitor with the potential to improve efficacy and overcome resistance to PARP inhibitors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"XZP-6924: A potent and highly selective USP1 inhibitor with the potential to improve efficacy and overcome resistance to PARP inhibitors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-02 DNA damage and repair,,"},{"Key":"Keywords","Value":"Triple-negative breast cancer (TNBC),DNA repair,PARP Resistance,USP1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Uday Kumar Surampudi<sup><\/sup>, <b>Prashant Kashinath Bhavar<\/b><sup><\/sup><br><br\/>Vrise Therapeutics Inc., Cambridge, MA","CSlideId":"","ControlKey":"2f845f62-edf0-4294-9620-245356e6d624","ControlNumber":"10895","DisclosureBlock":"&nbsp;<b>U. K. Surampudi, <\/b> None..<br><b>P. K. Bhavar, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10518","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB270","PresenterBiography":null,"PresenterDisplayName":"Prashant Bhavar, MS","PresenterKey":"115d09ea-8e12-4997-b0cc-bef0e92a7e3a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB270. VRTX531, a potent and selective inhibitor of USP1 for treatment of BRAC1\/2mut and HRD+ cancers","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"VRTX531, a potent and selective inhibitor of USP1 for treatment of BRAC1\/2mut and HRD+ cancers","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-02 DNA damage and repair,,"},{"Key":"Keywords","Value":"DNA repair inhibition,combination,PARP inhibitors,USP1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Yang<\/b>, Z. Li, L. Zhou, F. Zhou, X. Qin, L. Xue, P. Xu, J. Tang, W. Wang, R. Tang; <br\/>Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China","CSlideId":"","ControlKey":"e43d0108-0729-46bb-972f-5ab3e76b86c6","ControlNumber":"10340","DisclosureBlock":"<b>&nbsp;S. Yang, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>Z. Li, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>L. Zhou, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>F. Zhou, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>X. Qin, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>L. Xue, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>P. Xu, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>J. Tang, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>W. Wang, <\/b> <br><b>Simcere Zaiming<\/b> Employment. <br><b>R. Tang, <\/b> <br><b>Simcere Zaiming<\/b> Employment.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10519","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB271","PresenterBiography":null,"PresenterDisplayName":"Shuqun Yang, PhD","PresenterKey":"a5a5c523-b569-4ce9-b699-e1c4a3852d41","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB271. Synergistic anti-tumor efficacy in olaparib-sensitive and -resistant models via simultaneously inhibition of USP1 and PARP","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Synergistic anti-tumor efficacy in olaparib-sensitive and -resistant models via simultaneously inhibition of USP1 and PARP","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-02 DNA damage and repair,,"},{"Key":"Keywords","Value":"PARP inhibitors,Bromodomain and Extra-Terminal domain (BET) ,Replication stress,Homologous recombination ,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Xin Peng<\/b><sup>1<\/sup>, Xin Huang<sup>1<\/sup>, Shaolu Zhang<sup>1<\/sup>, Naixin Zhang<sup>1<\/sup>, Shengfan Huang<sup>1<\/sup>, Yingying Wang<sup>1<\/sup>, Zhenxing Zhong<sup>1<\/sup>, Shan Zhu<sup>1<\/sup>, Haiwang Gao<sup>1<\/sup>, Zixiang Yu<sup>1<\/sup>, Xiaotong Yan<sup>1<\/sup>, Zhennan Tao<sup>2<\/sup>, Yuxiang Dai<sup>2<\/sup>, Zhe Zhang<sup>1<\/sup>, Xi Chen<sup>3<\/sup>, Feng Wang<sup>1<\/sup>, Francois X. Claret<sup>4<\/sup>, Ning Ji<sup>1<\/sup>, Yuxu Zhong<sup>5<\/sup>, Dexin Kong<sup>1<\/sup><br><br\/><sup>1<\/sup>Tianjin Medical University, Tianjin, China,<sup>2<\/sup>Nanjing University, Nanjing, China,<sup>3<\/sup>Tianjin Eye Hospital, Tianjin, China,<sup>4<\/sup>MD Aanderson Cancer center, Houston, TX,<sup>5<\/sup>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China","CSlideId":"","ControlKey":"ba228989-255f-4d3c-aa67-2b37ce4d0ebb","ControlNumber":"10546","DisclosureBlock":"&nbsp;<b>X. Peng, <\/b> None..<br><b>X. Huang, <\/b> None..<br><b>S. Zhang, <\/b> None..<br><b>N. Zhang, <\/b> None..<br><b>S. Huang, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>Z. Zhong, <\/b> None..<br><b>S. Zhu, <\/b> None..<br><b>H. Gao, <\/b> None..<br><b>Z. Yu, <\/b> None..<br><b>X. Yan, <\/b> None..<br><b>Z. Tao, <\/b> None..<br><b>Y. Dai, <\/b> None..<br><b>Z. Zhang, <\/b> None..<br><b>X. Chen, <\/b> None..<br><b>F. Wang, <\/b> None..<br><b>F. Claret, <\/b> None..<br><b>N. Ji, <\/b> None..<br><b>Y. Zhong, <\/b> None..<br><b>D. Kong, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10520","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB272","PresenterBiography":null,"PresenterDisplayName":"Xin Peng, PhD","PresenterKey":"620bc9bb-5f87-4d98-8fb0-0efb4176c7d0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB272. Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma multiforme","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma multiforme","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-02 DNA damage and repair,,"},{"Key":"Keywords","Value":"PARP inhibitors,HDAC inhibitor,Small molecule inhibitor,DNA damage response,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Truong<sup>1<\/sup>, <b>L. Ramos<\/b><sup>1<\/sup>, B. Zhai<sup>1<\/sup>, F. Ghaidi<sup>1<\/sup>, M. Marzban<sup>1<\/sup>, H. Adomat<sup>1<\/sup>, X. Chen<sup>2<\/sup>, J. Langlands<sup>2<\/sup>, D. Brown<sup>2<\/sup>, J. Bacha<sup>2<\/sup>, C. Collins<sup>1<\/sup>, P. H. Sorensen<sup>3<\/sup>, W. Shen<sup>2<\/sup>, M. Daugaard<sup>1<\/sup>; <br\/><sup>1<\/sup>Vancouver Prostate Center, Vancouver, BC, Canada, <sup>2<\/sup>Rakovina Therapeutics Inc., Vancouver, BC, Canada, <sup>3<\/sup>British Columbia Cancer Research Centre, Vancouver, BC, Canada","CSlideId":"","ControlKey":"07883a50-ac79-4da2-b5a7-93ff3018f1ff","ControlNumber":"10747","DisclosureBlock":"<b>&nbsp;S. Truong, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Stock Option. <br><b>L. Ramos, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Stock Option. <br><b>B. Zhai, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Stock Option. <br><b>F. Ghaidi, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Stock Option. <br><b>M. Marzban, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Stock Option.<br><b>H. Adomat, <\/b> None.&nbsp;<br><b>X. Chen, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Independent Contractor. <br><b>J. Langlands, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Employment, Independent Contractor, Stock. <br><b>D. Brown, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Employment, Stock. <br><b>J. Bacha, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Employment, Stock.<br><b>C. Collins, <\/b> None..<br><b>P. H. Sorensen, <\/b> None.&nbsp;<br><b>W. Shen, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Patent. <br><b>M. Daugaard, <\/b> <br><b>Rakovina Therapeutics Inc.<\/b> Employment, Stock.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10521","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB273","PresenterBiography":null,"PresenterDisplayName":"Louise Ramos, MSc","PresenterKey":"8982bed3-b2d9-45d2-9f91-4825ed3fdd83","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB273. Pharmacological synthetic lethality by co-inhibition of PARP and HDAC enzymes","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Pharmacological synthetic lethality by co-inhibition of PARP and HDAC enzymes","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-03 Identification of molecular targets,,"},{"Key":"Keywords","Value":"Pancreatic cancer,HIKESHI,Target discovery,Prognostic markers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Bilguun Erkhem-Ochir<\/b><sup>1<\/sup>, Takehiko Yokobori<sup>1<\/sup>, Gendensuren Dorjkhorloo<sup>2<\/sup>, Haruka Okami<sup>2<\/sup>, Takaomi Seki<sup>2<\/sup>, Norifumi Harimoto<sup>2<\/sup>, Ryo Muranushi<sup>2<\/sup>, Kouki Hoshino<sup>2<\/sup>, Kei Hagiwara<sup>2<\/sup>, Norihiro Ishii<sup>2<\/sup>, Mariko Tsukagoshi<sup>2<\/sup>, Kenichiro Araki<sup>2<\/sup>, Hiroshi Saeki<sup>2<\/sup>, Ken Shirabe<sup>2<\/sup><br><br\/><sup>1<\/sup>Gunma University Initiative for Advanced Research, Maebashi, Japan,<sup>2<\/sup>Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan","CSlideId":"","ControlKey":"489a9e2c-5dd4-4654-85c0-ace54047ecbd","ControlNumber":"10582","DisclosureBlock":"&nbsp;<b>B. Erkhem-Ochir, <\/b> None..<br><b>T. Yokobori, <\/b> None..<br><b>G. Dorjkhorloo, <\/b> None..<br><b>H. Okami, <\/b> None..<br><b>T. Seki, <\/b> None..<br><b>N. Harimoto, <\/b> None..<br><b>R. Muranushi, <\/b> None..<br><b>K. Hoshino, <\/b> None..<br><b>K. Hagiwara, <\/b> None..<br><b>N. Ishii, <\/b> None..<br><b>M. Tsukagoshi, <\/b> None..<br><b>K. Araki, <\/b> None..<br><b>H. Saeki, <\/b> None..<br><b>K. Shirabe, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10522","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB274","PresenterBiography":null,"PresenterDisplayName":"Bilguun Erkhem-Ochir","PresenterKey":"413bfffb-8bb3-484e-8afa-dae38edaae9b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB274. Nuclear transporter HIKESHI is a novel independent poor overall survival for pancreatic cancer; targeting can inhibit pancreatic cancer growth via HSP70 suppression","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Nuclear transporter HIKESHI is a novel independent poor overall survival for pancreatic cancer; targeting can inhibit pancreatic cancer growth via HSP70 suppression","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-03 Identification of molecular targets,,"},{"Key":"Keywords","Value":"Immunogenic cell death,Antibody-drug conjugate (ADC),Drug resistance,Breast cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>O. Saatci<\/b><sup>1<\/sup>, M. Gedik<sup>1<\/sup>, N. Oberholtzer<sup>1<\/sup>, M. Uner<sup>2<\/sup>, O. Akbulut<sup>3<\/sup>, M. Cetin<sup>1<\/sup>, M. Aras<sup>4<\/sup>, K. Ibis<sup>5<\/sup>, B. Caliskan<sup>5<\/sup>, E. Banoglu<sup>5<\/sup>, S. Wiemann<sup>6<\/sup>, A. Uner<sup>2<\/sup>, S. Aksoy<sup>7<\/sup>, S. Mehrotra<sup>1<\/sup>, O. Sahin<sup>1<\/sup>; <br\/><sup>1<\/sup>The Medical University of South Carolina (MUSC), Charleston, SC, <sup>2<\/sup>Hacettepe University, Ankara, Turkey, <sup>3<\/sup>Bilkent University, Ankara, Turkey, <sup>4<\/sup>University of South Carolina, Columbia, SC, <sup>5<\/sup>Gazi University, Ankara, Turkey, <sup>6<\/sup>German Cancer Research Center (DKFZ), Heidelberg, Germany, <sup>7<\/sup>Hacettepe University Cancer Institute, Ankara, Turkey","CSlideId":"","ControlKey":"6cadf9b6-2b34-4e23-a37f-817c31ff23e9","ControlNumber":"10888","DisclosureBlock":"&nbsp;<b>O. Saatci, <\/b> None..<br><b>M. Gedik, <\/b> None..<br><b>N. Oberholtzer, <\/b> None..<br><b>M. Uner, <\/b> None..<br><b>O. Akbulut, <\/b> None..<br><b>M. Cetin, <\/b> None..<br><b>M. Aras, <\/b> None..<br><b>K. Ibis, <\/b> None..<br><b>B. Caliskan, <\/b> None..<br><b>E. Banoglu, <\/b> None..<br><b>S. Wiemann, <\/b> None..<br><b>A. Uner, <\/b> None..<br><b>S. Aksoy, <\/b> None..<br><b>S. Mehrotra, <\/b> None.&nbsp;<br><b>O. Sahin, <\/b> <br><b>OncoCube Therapeutics LLC<\/b> Ozgur Sahin is the co-founder and manager of OncoCube Therapeutics LLC. <br><b>LoxiGen, Inc<\/b> Ozgur Sahin is the founder and president of LoxiGen, Inc. <br><b>A2A Pharmaceuticals<\/b> Ozgur Sahin is the member of the scientific advisory board of A2A Pharmaceuticals.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10523","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB275","PresenterBiography":null,"PresenterDisplayName":"Ozge Saatci, BS;MS","PresenterKey":"d384fb7e-177c-4b9f-b7fb-a28267aa9fd9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB275. Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer<u><\/u>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer<u><\/u>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET06-04 Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes,,"},{"Key":"Keywords","Value":"Diagnostic marker,Thyroid cancer,BRAF,Mutation detection,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. R. Gastelum-Quiroz<\/b><sup>1<\/sup>, A. Ross-Orozco<sup>2<\/sup>, M. A. lvarez-Arrazola<sup>3<\/sup>, E. Arambula-Meraz<sup>4<\/sup>, K. L. Morales-Hernndez<sup>1<\/sup>, H. M. Tolosa-Lerma<sup>5<\/sup>, F. Luque-Ortega<sup>6<\/sup>, P. Y. Snchez-Aboytes<sup>5<\/sup>, N. Garca-Magallanes<sup>5<\/sup>; <br\/><sup>1<\/sup>Posgrado en Ciencias Biomdicas,  Facultad de Ciencias Qumico-Biolgicas, Universidad Autnoma de Sinaloa, Culiacn, Mexico, <sup>2<\/sup>Posgrado en Ciencias Biomdicas, Facultad de Ciencias Qumico-Biolgicas, Universidad Autnoma de Sinaloa, Culiacn, Mexico, <sup>3<\/sup>lvarez y Arrazola Radilogos, Mazatln, Mexico, <sup>4<\/sup>Laboratorio de Gentica y Biologa Molecular, Facultad de Ciencias Qumico-Biolgicas, Universidad AutnomadeSinaloa, Culiacn, Mexico, <sup>5<\/sup>Laboratorio de Biomedicina y Biologa Molecular, Universidad Politcnica de Sinaloa, Mazatln, Mexico, <sup>6<\/sup>Laboratorio de Ciencias Bsicas, Facultad de Odontologa, Universidad AutnomadeSinaloa, Culiacn, Mexico","CSlideId":"","ControlKey":"466ababe-686d-4345-8fa5-021eace13951","ControlNumber":"10599","DisclosureBlock":"&nbsp;<b>A. R. Gastelum-Quiroz, <\/b> None..<br><b>A. Ross-Orozco, <\/b> None..<br><b>M. A. lvarez-Arrazola, <\/b> None..<br><b>E. Arambula-Meraz, <\/b> None..<br><b>K. L. Morales-Hernndez, <\/b> None..<br><b>H. M. Tolosa-Lerma, <\/b> None..<br><b>F. Luque-Ortega, <\/b> None..<br><b>P. Y. Snchez-Aboytes, <\/b> None..<br><b>N. Garca-Magallanes, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10524","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB276","PresenterBiography":null,"PresenterDisplayName":"Anette Gastelum Quiroz, BS","PresenterKey":"84551acd-f443-4541-a408-44271adf2e8b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB276. qPCR in the diagnosis of papillary thyroid cancer: Assessment of BRAF V600E mutation in FNA biopsies of thyroid nodules","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"qPCR in the diagnosis of papillary thyroid cancer: Assessment of BRAF V600E mutation in FNA biopsies of thyroid nodules","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET07-05 Pharmacokinetics and pharmacodynamics,,"},{"Key":"Keywords","Value":"Osimertinib,NSCLC,Efficacy,Pharmacokinetics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Yang<\/b><sup>1<\/sup>, D. Olabode<sup>1<\/sup>, A. Sawant<sup>1<\/sup>, K. Vishwanathan<sup>1<\/sup>, S. Bachina<sup>1<\/sup>, A. Todd<sup>2<\/sup>, D. Ghiorghiu<sup>2<\/sup>, Y. Rukazenkov<sup>2<\/sup>, A. Phipps<sup>3<\/sup>, D. Zhou<sup>1<\/sup>, A. Shahraz<sup>1<\/sup>; <br\/><sup>1<\/sup>AstraZeneca R&D Boston, Waltham, MA, <sup>2<\/sup>AstraZeneca, Cambridge, United Kingdom, <sup>3<\/sup>AstraZeneca R&D, Cambridge, United Kingdom","CSlideId":"","ControlKey":"7d83422d-561d-466f-b4f8-65e2bf9135cd","ControlNumber":"10562","DisclosureBlock":"<b>&nbsp;J. Yang, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Travel. <br><b>D. Olabode, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>A. Sawant, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>Pfizer<\/b> Stock. <br><b>K. Vishwanathan, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>S. Bachina, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>A. Todd, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>D. Ghiorghiu, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>Y. Rukazenkov, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>A. Phipps, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>D. Zhou, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>A. Shahraz, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10525","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB277","PresenterBiography":null,"PresenterDisplayName":"Jincheng Yang","PresenterKey":"2e271408-6fba-4780-a2d3-e106817c4fc3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB277. Exposure response and safety analysis of osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC patients with EGFRm (FLAURA2)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Exposure response and safety analysis of osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC patients with EGFRm (FLAURA2)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET07-05 Pharmacokinetics and pharmacodynamics,,"},{"Key":"Keywords","Value":"Irinotecan,Pharmacokinetics\/Pharmacodynamics,SN-38,optimal dosage regimen,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Young<\/b>, S. Bigora, P. Franks, M. Nyberg, Y. Madden; <br\/>Processa Pharmaceuticals, Inc., Hanover, MD","CSlideId":"","ControlKey":"f275a5c6-dbbc-4e88-a7a5-acd8681ad1c7","ControlNumber":"10713","DisclosureBlock":"<b>&nbsp;D. Young, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Fiduciary Officer, Stock. <br><b>S. Bigora, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Fiduciary Officer, Stock. <br><b>P. Franks, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Stock. <br><b>M. Nyberg, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Stock. <br><b>Y. Madden, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Stock.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10526","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB278","PresenterBiography":null,"PresenterDisplayName":"David Young, PhD;Pharm D","PresenterKey":"e199f50a-5bd6-4a2b-803c-583fc92102c2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB278. Application of phase 1 and pre-clinical data to assist in determining the optimal dosage regimen for cancer drugs using the principles of Project Optimus","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Application of phase 1 and pre-clinical data to assist in determining the optimal dosage regimen for cancer drugs using the principles of Project Optimus","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET08-06 Radiotherapeutic combinations,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Radiation,Cancer therapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Son<\/b><sup>1<\/sup>, E. Ju<sup>1<\/sup>, J. Park<sup>1<\/sup>, S. Shin<sup>1<\/sup>, E. Ko<sup>1<\/sup>, M. Kwon<sup>1<\/sup>, H. Lee<sup>1<\/sup>, B. Seo<sup>2<\/sup>, S. Lee<sup>2<\/sup>, S. Park<sup>1<\/sup>, S. Jeong<sup>1<\/sup>, S. Song<sup>1<\/sup>, E. Choi<sup>1<\/sup>; <br\/><sup>1<\/sup>Asan Medical Center (AMC), Seoul, Korea, Republic of, <sup>2<\/sup>IntoCell Inc., Daejeon, Korea, Republic of","CSlideId":"","ControlKey":"af88c726-813a-44e0-bb27-be355b78f4e8","ControlNumber":"10573","DisclosureBlock":"&nbsp;<b>G. Son, <\/b> None..<br><b>E. Ju, <\/b> None..<br><b>J. Park, <\/b> None..<br><b>S. Shin, <\/b> None..<br><b>E. Ko, <\/b> None..<br><b>M. Kwon, <\/b> None..<br><b>H. Lee, <\/b> None..<br><b>B. Seo, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>S. Park, <\/b> None..<br><b>S. Jeong, <\/b> None..<br><b>S. Song, <\/b> None..<br><b>E. Choi, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10527","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"24","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB279","PresenterBiography":null,"PresenterDisplayName":"Gawon Son, MS","PresenterKey":"07be68e6-36ea-4ef6-a303-d5849ac39154","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB279. The combination therapy with B7-H3 antibody drug conjugates for effective radiation treatment","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The combination therapy with B7-H3 antibody drug conjugates for effective radiation treatment","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET08-06 Radiotherapeutic combinations,,"},{"Key":"Keywords","Value":"Glioblastoma,Radiotherapy,antiviral RNA sensing,Immune response,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Meng Jiao<\/b><sup><\/sup>, Christopher  J.  Pirozzi<sup><\/sup>, Chen Yu<sup><\/sup>, Xuhui Bao<sup><\/sup>, Mengjie Hu<sup><\/sup>, Dong Pan<sup><\/sup>, Sejiro Littleton<sup><\/sup>, Nathan Reynolds<sup><\/sup>, Daniel  R.  Saban<sup><\/sup>, Fang Li<sup><\/sup>, Chuan-yuan Li<sup><\/sup><br><br\/>Duke University School of Medicine, Durham, NC","CSlideId":"","ControlKey":"239853d0-ca0d-4b9c-9855-fb10caaff531","ControlNumber":"10241","DisclosureBlock":"&nbsp;<b>M. Jiao, <\/b> None..<br><b>C. J. Pirozzi, <\/b> None..<br><b>C. Yu, <\/b> None..<br><b>X. Bao, <\/b> None..<br><b>M. Hu, <\/b> None..<br><b>D. Pan, <\/b> None..<br><b>S. Littleton, <\/b> None..<br><b>N. Reynolds, <\/b> None..<br><b>D. R. Saban, <\/b> None..<br><b>F. Li, <\/b> None..<br><b>C. Li, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10528","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"25","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB280","PresenterBiography":"","PresenterDisplayName":"Meng Jiao, PhD","PresenterKey":"f729413d-a3e1-4de6-9127-1990598fbc2f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB280. Enhancing glioblastoma radiotherapy by COMT inhibition","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Enhancing glioblastoma radiotherapy by COMT inhibition","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET08-07 Theranostics\/radiotheranostics,,"},{"Key":"Keywords","Value":"Theranostics,Integrins,Solid tumors,Radioimmunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"L. M. De Souza Cordeiro, K. C. Atkinson, F. Jia, A. Aivazian, G. E. Smith, I. Wilson, <b>A. Mascioni<\/b>; <br\/>ImaginAb Inc, Inglewood, CA","CSlideId":"","ControlKey":"4737ffaa-1da3-496d-b5d3-5cfe0a36eb2f","ControlNumber":"10309","DisclosureBlock":"<b>&nbsp;L. M. De Souza Cordeiro, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>K. C. Atkinson, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>F. Jia, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>A. Aivazian, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>G. E. Smith, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>I. Wilson, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>A. Mascioni, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment, Stock Option.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10529","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"26","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB281","PresenterBiography":null,"PresenterDisplayName":"Alessandro Mascioni, PhD","PresenterKey":"10661826-7a28-4ea5-939a-ce3951d21006","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB281. A preclinical therapeutic study of minibody 177Lu-DOTAGA-IAB56 targeting &#945;V&#946;6 for the treatment of pancreatic cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A preclinical therapeutic study of minibody 177Lu-DOTAGA-IAB56 targeting &#945;V&#946;6 for the treatment of pancreatic cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++ET08-07 Theranostics\/radiotheranostics,,"},{"Key":"Keywords","Value":"Solid tumors,Theranostics,Radioimmunotherapy,Antibody engineering,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"K. C. Atkinson, L. M. De Souza Cordeiro, F. Jia, A. Aivazian, G. E. Smith, I. Wilson, <b>A. Mascioni<\/b>; <br\/>ImaginAb Inc, Inglewood, CA","CSlideId":"","ControlKey":"32c662dd-0b49-4dbc-afec-90c31bd232ac","ControlNumber":"10322","DisclosureBlock":"<b>&nbsp;K. C. Atkinson, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>L. M. De Souza Cordeiro, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>F. Jia, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>A. Aivazian, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>G. E. Smith, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>I. Wilson, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment. <br><b>A. Mascioni, <\/b> <br><b>ImaginAb, Inc.<\/b> Employment, Stock Option.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10530","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"27","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"LB282","PresenterBiography":null,"PresenterDisplayName":"Alessandro Mascioni, PhD","PresenterKey":"10661826-7a28-4ea5-939a-ce3951d21006","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"LB282. Therapeutic efficacy and dosimetry for a 177-lutetium radiolabeled minibody targeting DLL3 in a preclinical model of small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"599","SessionOnDemand":"False","SessionTitle":"Late-Breaking Research: Experimental and Molecular Therapeutics 3","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Therapeutic efficacy and dosimetry for a 177-lutetium radiolabeled minibody targeting DLL3 in a preclinical model of small cell lung cancer","Topics":null,"cSlideId":""}]